[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573303":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":16,"locations":25,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"PROCEDURE","stereotactic radiotherapy ablation","Single dose of 25 Gy up to 32.5 Gy on the myocardium in patients with therapy-refractory ventricular tachycardia",[14,15],"STAR","stereotactic body radiotherapy",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Bert Vandenberk, MD PhD","CONTACT","+3216338686","bert.vandenberk@uzleuven.be",{"name":23,"role":19,"phone":7,"phoneExt":7,"email":24},"Patrick Berkovic, MD PhD","patrick.berkovic@uzleuven.be",[26],{"facility":27,"status":28,"city":29,"state":7,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"UZ Leuven","RECRUITING","Leuven","3000","Belgium","BE",{"type":34,"coordinates":35},"Point",[36,37],4.70093,50.87959,{"lat":37,"lon":36},[40],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100573303","cardiac-radiotherapy-for-ventricular-tachycardia-ii-100573303",false,"NCT06744530","Cardiac RadiothErapy for VEntricular Tachycardia II","Cardiac RadiothErapy for VEntricular Tachycardia II - a Prospective Observational Cohort Study","CREVET II","Inclusion Criteria:\n\n* Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion\n* Ability to give a written informed consent and willingness to return for follow-up\n\nExclusion Criteria:\n\n* Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \\\u003C 6 months in the absence of VT\n* Any condition that is deemed a contraindication in the judgment of the investigators","ALL","18 Years",{"count":54,"type":55},50,"ESTIMATED","4 Years","OBSERVATIONAL","Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.",[60],"Ventricular Tachycardia (VT)",[62,14,63],"ventricular tachycardia","Stereotactic radiotherapy","2026-04-28",{"date":66,"type":67},"2026-04-29","ACTUAL",{"date":69,"type":67},"2025-01-01",{"date":71,"type":55},"2034-12",{"name":5,"class":6},1]